Prestige Consumer Healthcare Inc. (NYSE:PBH) Insider Sells $735,585.95 in Stock

Prestige Consumer Healthcare Inc. (NYSE:PBH) insider William P’pool sold 8,987 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total transaction of $735,585.95. Following the completion of the transaction, the insider now owns 20,058 shares of the company’s stock, valued at approximately $1,641,747.30. The trade was a 30.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Prestige Consumer Healthcare Trading Up 0.6 %

Shares of PBH stock traded up $0.49 on Thursday, hitting $82.81. 337,716 shares of the stock traded hands, compared to its average volume of 250,663. The firm’s 50-day moving average price is $72.98 and its two-hundred day moving average price is $70.09. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. The stock has a market capitalization of $4.09 billion, a PE ratio of 20.05, a PEG ratio of 2.30 and a beta of 0.47. Prestige Consumer Healthcare Inc. has a twelve month low of $56.61 and a twelve month high of $83.83.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.09. The firm had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. Prestige Consumer Healthcare’s revenue was down .9% on a year-over-year basis. During the same period in the previous year, the firm earned $1.07 EPS. As a group, analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on PBH. Jefferies Financial Group reaffirmed a “hold” rating and issued a $76.00 price target (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. DA Davidson reaffirmed a “buy” rating and issued a $95.00 price target on shares of Prestige Consumer Healthcare in a research note on Monday. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Prestige Consumer Healthcare has an average rating of “Moderate Buy” and a consensus price target of $94.20.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several hedge funds have recently added to or reduced their stakes in PBH. Ariel Investments LLC grew its position in shares of Prestige Consumer Healthcare by 10.7% during the second quarter. Ariel Investments LLC now owns 2,835,203 shares of the company’s stock worth $195,204,000 after acquiring an additional 274,212 shares during the last quarter. Victory Capital Management Inc. lifted its holdings in Prestige Consumer Healthcare by 9.0% in the second quarter. Victory Capital Management Inc. now owns 2,074,460 shares of the company’s stock valued at $142,827,000 after acquiring an additional 171,357 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in Prestige Consumer Healthcare by 19.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,575,170 shares of the company’s stock valued at $113,570,000 after acquiring an additional 255,045 shares during the period. Congress Asset Management Co. lifted its holdings in Prestige Consumer Healthcare by 7.8% in the third quarter. Congress Asset Management Co. now owns 865,123 shares of the company’s stock valued at $62,375,000 after acquiring an additional 62,411 shares during the period. Finally, Boston Trust Walden Corp acquired a new position in shares of Prestige Consumer Healthcare during the 3rd quarter worth $41,785,000. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.